Indietro

Teva Pharma Industries Ltd ADR

Ticker: TEVA ISIN: US8816242098
Aggiungi al portafoglio Analisi del portafoglio in 2min
Stock Large-cap Trading above 200-day average Near 52-week high
Capitalizzazione
20,72 Mld $
Forward P/E
6,96
Profit margin
-0,94%
Revenue growth QoQ
0,30%
Beta
0,62
37,34 $ 1,44%
Prezzo al 2026-08-21 · NYSE

Performance per periodo

Rendimenti cumulativi
1 Month +21,19%
6 Months +10,12%
1 Year +106,07%
5 Years +31,60% p.a.+294,30%
10 Years -2,70% p.a.-23,92%
Since inception +4,17% p.a.+177,74%
Rendimenti per anno
YTD +19,64%
2025 +41,61%
2024 +111,11%
2023 +14,47%
2022 +13,86%
2021 -16,99%

Key stats

Market cap
20,72 Mld
Beta
0,62
52-week range
12.47 - 22.80
50-day MA
16,72
200-day MA
17,21
Section 1

Business overview

Company profile data from fundamentals.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Country Israel
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -2,42%
ROA 5,37%
Profit margin -0,94%
Operating margin 21,41%
PEG ratio 1,29
Revenue/share TTM 14,61
Revenue TTM 16,63 Mld
EBITDA 4,52 Mld
Gross profit TTM 8,25 Mld
Beta 0,62

Valuation

Trailing P/E 0,00
Forward P/E 6,96
P/B 3,03
P/S 1,25
EV/EBITDA 19,12
EV/Revenue 2,18

ESG Scores

Total ESG 58,8
Environment 77,0
Social 47,2
Governance 65,3
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 2,58
Quarterly earnings growth 40,00%
Revenue TTM 16,63 Mld
Reported quarters 120
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0,00%
Ex-dividend date 2017-11-27
Split factor 2:1
Last split date 2004-07-01
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 23,56 $
Analyst rating 4.4546

Ownership & short interest

Shares outstanding 1,15 Mld
Shares float 1,14 Mld
Institutional ownership 66,22%
Insider ownership 0,20%
Short ratio 4,27
Short % of float 4,37%

Details

Instrument metadata and source update timestamps.

Symbol TEVA
Name Teva Pharma Industries Ltd ADR
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US8816242098
Country USA
Code + exchange TEVA.NYSE
Fundamentals updated 2025-08-19

Le informazioni fornite su questa piattaforma hanno solo scopo informativo e non devono essere considerate consulenza finanziaria o di investimento. Insightfolio non fornisce consulenza d'investimento, raccomandazioni personalizzate o indicazioni relative all'acquisto, alla detenzione o alla vendita di strumenti finanziari. Gli strumenti e i contenuti sono destinati esclusivamente a finalita educative e non sono adattati alle circostanze individuali, alle esigenze finanziarie o agli obiettivi personali.

Insightfolio non si assume alcuna responsabilita per l'accuratezza, la completezza o l'affidabilita delle informazioni presentate. Gli utenti sono gli unici responsabili della verifica delle informazioni e dell'assunzione di decisioni indipendenti basate sulla propria ricerca e su un'attenta valutazione. L'uso della piattaforma non deve sostituire la consulenza di professionisti finanziari qualificati.

Gli investimenti comportano rischi. Gli utenti devono essere consapevoli che il valore degli investimenti puo variare e che i rendimenti passati non sono indicativi di risultati futuri. Le decisioni di investimento devono basarsi sugli obiettivi finanziari personali, sulla tolleranza al rischio e su una valutazione indipendente delle informazioni rilevanti.

Insightfolio non approva ne garantisce l'idoneita di alcun prodotto finanziario, titolo o strategia specifica. Eventuali proiezioni, previsioni o scenari ipotetici presentati sulla piattaforma hanno solo scopo illustrativo e non costituiscono garanzia di risultati futuri.

Accedendo ai servizi, alle informazioni o ai contenuti offerti da Insightfolio, gli utenti riconoscono e accettano i presenti termini di esclusione di responsabilita. Se non accetti questi termini, ti invitiamo a non utilizzare la piattaforma.

Instrument logos provided by Elbstream.